246 related articles for article (PubMed ID: 12516966)
1. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
[TBL] [Abstract][Full Text] [Related]
2. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
Jin S; Gorfajn B; Faircloth G; Scotto KW
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6775-9. PubMed ID: 10841572
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Beumer JH; Buckle T; Ouwehand M; Franke NE; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Invest New Drugs; 2007 Feb; 25(1):1-7. PubMed ID: 16633714
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
5. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
7. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells.
Zhong X; Safa AR
J Biol Chem; 2004 Apr; 279(17):17134-41. PubMed ID: 14769796
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
9. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.
Guo X; Ma N; Wang J; Song J; Bu X; Cheng Y; Sun K; Xiong H; Jiang G; Zhang B; Wu M; Wei L
BMC Cancer; 2008 Dec; 8():375. PubMed ID: 19091131
[TBL] [Abstract][Full Text] [Related]
10. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
11. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
[TBL] [Abstract][Full Text] [Related]
12. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma.
Nakajima A; Yamamoto Y; Taura K; Hata K; Fukumoto M; Uchinami H; Yonezawa K; Yamaoka Y
Int J Oncol; 2004 Mar; 24(3):635-45. PubMed ID: 14767548
[TBL] [Abstract][Full Text] [Related]
15. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
[TBL] [Abstract][Full Text] [Related]
16. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
17. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1.
Zhao L; Jin X; Xu Y; Guo Y; Liang R; Guo Z; Chen T; Sun Y; Ding X
J Exp Clin Cancer Res; 2010 Jul; 29(1):98. PubMed ID: 20642825
[TBL] [Abstract][Full Text] [Related]
18. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
19. The role of c-myc in regulating mdr1 gene expression in tumor cell line KB.
He Y; Zhang J; Zhang J; Yuan Y
Chin Med J (Engl); 2000 Sep; 113(9):848-51. PubMed ID: 11776085
[TBL] [Abstract][Full Text] [Related]
20. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
